TRC051384 |cas 867164-40-7|DC Chemicals

Cas No.:	867164-40-7
Synonyms:	TRC 051384; TRC-051384
SMILES:	O=C(/C([H])=C(C1=NC(N2CCOCC2)=CC=C1)[H])C3=CC=C(C=C3)N/C(O)=N/CCN4CCOCC4
Formula:	C₂₅H₃₁N₅O₄
M.Wt:	465.54
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	TRC051384 is a heat shock protein 70 (HSP70) inducer.
Target:	HSP70
In Vivo:	Treatment with TRC051384 significantly reduces stroke associated neuronal injury (87% reduction in area of penumbra recruited to infarct, and 25% reduction in brain edema) and disability in a rat model of transient ischemic stroke even when administered 8 hours post onset of ischemia. Significant improvement in survival (50% by day2 and 67.3% by day 7) is observed with TRC051384 treatment initiated at 4 hours after ischemia onset. Induction of HSP70 by TRC051384 involves HSF1 activation and results in elevated chaperone and anti-inflammatory activity[1].
In Vitro:	TRC051384, dose dependently induces HSP70B mRNA by several hundred folds in both HeLa and rat primary mixed neurons. Treatment with TRC051384 results in significant dose-dependent increase in HSF1 transcriptional activity and recovery of luciferase activity. TRC051384 results in 60% inhibition at 6.25 μM and 90% inhibition at 12.5 μM of LPS-induced TNF-α expression in differentiated THP-1 cell line[1].
Cell Assay:	HeLa cell transiently co-transfected with heat shock elements-luciferase reporter and normalization vector, β-galactosidase are treated with vehicle or TRC051384 (12.5 and 25 μM) for 4 hours. Cell lysates are then prepared and analyzed for luciferase and β-galactosidase activity[1].
Animal Administration:	Rats: Injured hemispheres from vehicle treated animals and TRC051384 treated animals are collected at 10-hour post-initiation of tMCAo. Total RNA from each brain sample is extracted followed by cDNA preparation. Each sample of cDNA is analyzed[1].
References:	[1]. Mohanan A, et al. Delayed intervention in experimental stroke with TRC051384--a small molecule HSP70 inducer. Neuropharmacology. 2011 May;60(6):991-9.

Cat. No.	Product name	Field of application
DC74313	PLIHZ	PLIHZ is a small molecule inhibitor that targets DNAJA1, a member of the heat shock protein 40 (Hsp40) family. Derived from the natural compound plumbagin, PLIHZ specifically binds to the J domain of DNAJA1, which is crucial for its co-chaperone activity with Hsp70. By inhibiting DNAJA1, PLIHZ effectively reduces the levels of DNAJA1 and several conformational mutant p53 (mutp53) proteins, which are often stabilized in cancer cells and contribute to tumorigenesis.
DC74311	HLQ2H	HLQ2H (Msi3 inhibitor 2H) is a first-in-class, specific inhibitor of fungal Hsp110 molecular chaperone Msi3, inhibits the holdase activity of Msi3 (IC50=5.02 uM) as well as the growth and viability of C. albicans.
DC70662	NPX-800	NPX-800 is a potent, selective, oral heat shock factor 1 (HSF1) pathway inhibitor.
DC70417	Foldamer 33	Foldamer 33 is a small molecule HSP110 inhibitor, directly binds to the nucleotide-binding domain (NBD) of HSP110, blocks HSP110 chaperone function and colorectal cancer growth.Foldamer 33 significantly inhibit HSP110 anti-aggregating activity with IC50 of 87.8 uM.Foldamer 33 disrupts HSP110-STAT3 interaction with IC50 of 35.9 uM in competitive BLI assays.Foldamer 33 inhibits SW480 colorectal cancer cell proliferation, and (5 mg/kg) Foldamer 33 displays an anti-tumor effect (TGI of 40% and 60%) in mice bearing a colorectal cancer.
DC47938	NCT-58	NCT58(NCT 58) is a potent inhibitor of C-terminal HSP90. NCT-58 does not induce the heat shock response (HSR) due to its targeting of the C-terminal region and elicits anti-tumor activity via the simultaneous downregulation of HER family members as well as inhibition of Akt phosphorylation. NCT-58 kills Trastuzumab-resistant breast cancer stem-like cells. NCT-58 induces apoptosis in HER2-positive breast cancer cells.
DC46184	YUM70	YUM70 is a potent inhibitor of glucose-regulated protein 78 (GRP78) inhibitor with an IC50 of 1.5 μM. YUM70 induces endoplasmic reticulum (ER) stress-mediated apoptosis in pancreatic cancer.
DC44513	DTHIB	DTHIB is a direct and selective heat shock factor 1 (HSF1) inhibitor with a Kd of 160 nM for DTHIB binding to the HSF1 DNA binding domain (DBD). DTHIB inhibits HSF1 cancer gene signature (HSF1 CaSig) and selectively stimulates degradation of nuclear HSF1. DTHIB has potently anticancer activities and can be used for prostate cancer research.
DC44512	Conglobatin	Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active Hsp90 inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo.
DC40344	3-Phenyltoxoflavin	3-Phenyltoxoflavin, a derivative of Toxoflavin, is an Hsp90 inhibitor, with a Kd of 585 nM for the interaction of Hsp90-TPR2A. 3-Phenyltoxoflavin has anti-cancer activity.
DC8142	TAS-116	TAS-116 is a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models.